Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients

Inclusion Criteria:

1. Age between 18 and 75, both sex.

2. Left ventricular ejection fraction (LVEF)≤40% (ECHO).

3. NYNA functional class II~III.

4. Definitely diagnosed with chronic systolic heart failure (including medical records,symptoms and physical signs)and clinical symptom is steadily in the latest 1 month.

5. Receiving standard basic treatment of heart failure, has reached the objective dosageor the highest tolerated dosage for at least 1 month, or the dosage has not beenchanged for at least 1 month.

6. Capable of signing the informed consent form.

Exclusion Criteria:

1. Patients with acute myocardial infarction, Hypertrophic cardiomyopathy, constrictivepericarditis, significant valvular pathological change or congenital heart diseases,severe pulmonary artery hypertension.

2. Ischemic heart failure without recanalization or with recanalization in recent sixmonths.

3. Cardiac surgery or cerebrovascular accident within recent six months.

4. Preparing for heart transplantation or has received CRT treatment.

5. Serious hepatic or renal dysfunction caused by organic pathological changes (Cr＞2.0mg/dl, AST or ALT 5 times above the normal upper limit).

6. Patients need mechanical ventilation.

7. Systolic blood pressure <90mmHg or >160mmHg.

8. Patients with acute hemodynamic disorder or decompensation in the last 1 month.

9. Serious ventricular arrhythmia (multi-morphological premature ventricular contraction,frequent paroxysmal ventricular tachycardia).

10. Serum potassium <3.2 mmol/L or >5.5 mmol/L.

11. Pregnant or plan to pregnant.

12. Unmarried or married but not procreated women at child-bearing age.

13. Subject with a life expectancy less than 6 months as assessed by the investigator.

14. Patients who participated in any clinical trial in the recent three months.

15. History of any malignancy or suffering from cancer,or biopsy proven pre-malignantcondition (eg DICS or cervical atypia).

16. Evidence (physical examination,CXR,ECHO or other tests) shows some active malignancyor adenoidal hypertrophy or neoplasm has effect on heart function or endocrine system,eg pheochromocytoma or hyperthyroidism.

17. Judging by the investigator, the patients could not complete the study or adhere tothe study requirements (due to the management reasons or others).